Bromantane

It and bemitil are the only two actoprotectors ever licensed for human administration anywhere.

The mechanism is genuinely unusual, and it is worth stating precisely because the popular version of it overstates the case. Bromantane IS a dopamine reuptake inhibitor — it is simply a weak one.

Measured head-to-head in rat striatal synaptosomes against sydnocarb, ladasten inhibited dopamine transport with an IC50 of 3.56 micromolar versus sydnocarb's 28.66 nanomolar: roughly 125-fold weaker. An earlier study put synaptosomal blockade of dopamine and serotonin uptake at 50 micromolar and noradrenaline only above 500 micromolar, which is the quantitative basis for saying the noradrenergic arm is minimal.

Neither bromantane nor sydnocarb binds dopamine D1, D2 or D3 receptors, or serotonin 5-HT1A or 5-HT2A receptors, directly. So the honest framing is not 'not a reuptake inhibitor' but 'a weak, micromolar reuptake inhibitor whose distinguishing feature is something else entirely.'

That something else is transcription. A single 50 mg/kg oral dose in rats differentially regulates tyrosine hydroxylase mRNA and protein along with dopamine and L-DOPA content across the ventral tegmental area, nucleus accumbens, hypothalamus, striatum and hippocampus.

A companion study found the same dose raises gene expression of BOTH tyrosine hydroxylase and DOPA-decarboxylase, with L-DOPA and dopamine accumulation correlating with the transcriptional activity of those two genes; the authors read the early hours as increased dopamine release and the later effect as activation of de novo enzyme synthesis. The two arms are sequential, not exclusive.

Testing that directly under aromatic-amino-acid-decarboxylase blockade with NSD-1015, ladasten raised L-DOPA in nearly every brain structure except hippocampus and affected only dopamine parameters, not serotonin. There is even an epigenetic mechanism on record: bisulfite sequencing of the tyrosine hydroxylase 5'-flanking region showed increased cytosine demethylation of CpG islands at transcription-factor binding sites in rat hypothalamus after a single dose.

Direct in vivo release was separately demonstrated by striatal microdialysis in freely moving rats in 1995. Every one of these is a rat study, several of them from the developing laboratory, and none has been independently replicated by a Western group.

The anxiolytic half is indirect and stress-conditional, which matters more than it sounds. Bromantane does not appear to act as a benzodiazepine-site agonist; what it does is prevent the stress-induced REDUCTION in benzodiazepine-site binding at the GABA-A receptor.

In rats it was anxiolytic in one emotional-stress phenotype (MR) and not in another (MNRA), and it prevented the stress-induced change in 3H-diazepam binding only in the strain where it worked. The finding replicates in mice with 3H-flunitrazepam — but it is not specific to bromantane, since afobazole and noopept produced the same normalization.

Read plainly: this is restoration of a stress-perturbed system, not tonic anxiolysis in an unstressed animal, and it lines up with the healthy-volunteer result that the drug did nothing measurable in untired men.

The pharmacokinetics are the weakest part of the file and the easiest place to be misled. What is actually sourced, from a 2012 open-access review citing a 1997 Lancet correspondence: 42% oral bioavailability, time to maximum blood concentration of 4.0 hours in men and 2.75 hours in women, high lipophilicity with distribution into brain lipids and deposition in adipose tissue, hepatic metabolism dominated by hydroxylation at the 6-position of the adamantane cage, and metabolites still detectable in urine two weeks after a single administration.

What is NOT sourced anywhere is a half-life. The review says only that absorption is faster in women 'so the half-life is respectively lower than in men,' with no figure.

The one dedicated bromantane pharmacokinetics paper indexed in PubMed is Russian-language with no abstract available, so it cannot be read. Any specific half-life number circulating online is unverifiable, and this entry deliberately does not print one.

The two-week urinary window plus adipose deposition is the dose-relevant fact: it implies a long terminal phase and real accumulation with daily dosing, and it is why the compound stays detectable for anti-doping purposes long after the last dose.

On safety, the review literature's 'almost full absence of side effects' framing is sourced to the developers' own publications, and a primary rodent study contradicts it. Chronic bromantane at 30 mg/kg raised haemoglobin and leukocytes; at 150 and 600 mg/kg it raised those counts for about three months and then reduced erythrocytes, haemoglobin and leukocytes, producing reversible poikilocytosis, granulocytosis and agranulocytosis, with hepatocyte hypertrophy in liver tissue and haemosiderosis in the spleen.

The authors' own conclusion is that blood tissue is a target of bromantane toxicity. A two-month oral course produced sex-dependent and biphasic effects — motor activity fell in males and did not in females, early hypothermia gave way to slight hyperthermia in the second month, body weight rose in females and fell in males — though the animals normalized within two months of stopping and showed no behavioural signs of dependence.

An Irwin-protocol neurotoxicology screen found 30-300 mg/kg stimulating and 600-9,600 mg/kg suppressing behaviour, with mydriasis at every dose tested. And in the one reproductive study published in a Western journal, oral dosing of female rats for 16 days before mating cut litter size by 34.9% at 30 mg/kg and 44.2% at 600 mg/kg, with stillborn pups in every litter and fewer in controls — a result that sits directly against the developing group's own reports of positive effects on antenatal and postnatal development.

One comparison this entry refuses to make: there are ZERO PubMed records co-mentioning bromantane with modafinil, and zero co-mentioning it with amphetamine. Any such comparison is inference across two separate literatures, not a finding anyone has published.